Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Safety and efficacy of Rimegepant for the treatment of migraine in pediatric patients ≥6 to <18 years of age
Full IRB Study Title:
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
IRB Study ID: 1737932
View complete study information here.
Study Sponsor:
Biohaven Pharmaceuticals, Inc.
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Chad Gentry: cgentry@akronchildrens.org, 330-543-9809
Jessica Kracker: jkracker@akronchildrens.org, 330-543-0846
